Q-omics provides the consensus-scored DTNB profile across patient tissues and cancer cell-line models. DTNB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DTNB is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, DTNB protein abundance shows 22,467 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where DTNB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DTNB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DTNB survival associations across molecular data types. DTNB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DTNB RNA expression–survival associations across cancer types. High DTNB expression shows unfavorable associations in LIHC, MESO and BLCA, but favorable associations in LUSC, SKCM and ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for DTNB RNA expression.
This table summarizes DTNB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DTNB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DTNB shows lower tumor expression in KIRC and THCA and higher tumor expression in COAD, BLCA, LIHC and UCEC. The COAD box plot shows higher DTNB RNA expression in tumor versus normal tissue (log2 FC = +1.678, t-test p < 0.001).
This table shows molecular features associated with DTNB in patient tissues and cancer cell lines. In patient samples, DTNB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DTNB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
